SciClone Pharmaceuticals (SCLN)
SciClone Pharmaceuticals Profit Margin: 22.16%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SCLN Profit Margin Rankings
| Overall | 90th percentile | 401 of 4397 |
| Sector | 93rd percentile | 30 of 470 in Healthcare |
| Industry | 86th percentile | 5 of 37 in Drug Manufacturers - Other |
SCLN Profit Margin Range, Past 5 Years
| Minimum | -53.22% | Mar 2008 |
| Maximum | 33.40% | Jun 2009 |
| Average | 4.66% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these SCLN related companies
SCLN News
SciClone Pharmaceuticals to Present at Jefferies Global Healthcare Conference
May 29, 4:00PM Marketwire
May 29, 4:00PM Marketwire
$SCLN Upside Blowoff - 15 Minute Down Reversal - Red bar after 4 green bars
about 3 days ago by TradeIdeasQuant
about 3 days ago by TradeIdeasQuant
$SCLN should be trading near double current PT hardly any liabilities SciClone Pharmaceuticals Sees 2012 EPS 72c-EPS 78c > $SCLN
about 8 days ago by johnkelly
about 8 days ago by johnkelly
Listen to $SCLN Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3kfp
about 22 days ago by earningscast
about 22 days ago by earningscast
SciClone Pharmaceuticals to Report Financial Results for the First Quarter 2012 on May 9th
May 02, 6:00AM Marketwire
May 02, 6:00AM Marketwire
SciClone Files S-3 Registration Statement Prospectus Supplement Related to Sigma-Tau Transaction
Apr 30, 8:30AM Marketwire
Apr 30, 8:30AM Marketwire
$SCLN forms bullish "Symmetrical Continuation Triangle" chart pattern. http://stks.co/3HD0
about 52 days ago by RecogniaEvents
about 52 days ago by RecogniaEvents
$SCLN http://stks.co/3GlE Breakout confirmation, price & volume surge, trend likely to continue...http://tinyurl.com/SCLNpick
about 53 days ago by TraderHR
about 53 days ago by TraderHR
$AOL $CALL $SCLN $TITN showing up on my relative strength screen. staying in cash is the right thing to do today however.
about 53 days ago by markethumblesu
about 53 days ago by markethumblesu
Big question is will $SCLN EPS growth outpace its share price as its currently doing for the rest of 2012? $MRK $PFE http://stks.co/3GgL
about 53 days ago by EPS_MomentuM
about 53 days ago by EPS_MomentuM
$SCLN is still rallyin,its strategy to penetrate China which holds 1/5th world population is showing signs its working http://stks.co/3Ges
about 53 days ago by EPS_MomentuM
about 53 days ago by EPS_MomentuM
$SCLN keeps surging on 2 week old news? Overbought? http://stks.co/3GcO
about 53 days ago by EPS_MomentuM
about 53 days ago by EPS_MomentuM
Sciclone Pharmaceuticals (SCLN) Files $100M Mixed Shelf; 10M Common for Shareholders
Mar 15, 4:14PM Street Insider
Mar 15, 4:14PM Street Insider
$SCLN http://stks.co/2rZm All targets hit, at the open lol http://stks.co/2rZn <-chart details
about 78 days ago by BNGESG
about 78 days ago by BNGESG
Sciclone Pharma (SCLN) Reports Better-Than-Expected Q4 Results; Guides FY12
Mar 13, 4:08PM Street Insider
Mar 13, 4:08PM Street Insider
SciClone Pharmaceuticals (SCLN) Reports Results for Interim Analysis of Phase 2 SCV-07 Oral Mucositis Trial
Mar 02, 7:04AM Street Insider
Mar 02, 7:04AM Street Insider
SciClone Pharma (SCLN) Halted to Announce: Results of Phase 2 SCV-07 Oral Mucositis Trial Won't Meet Efficacy Endpoint
Mar 02, 7:02AM Street Insider
Mar 02, 7:02AM Street Insider
SciClone Announces Results of Interim Analysis of Phase 2 SCV-07 Oral Mucositis Trial
Mar 02, 7:00AM Marketwire
Mar 02, 7:00AM Marketwire
SciClone Pharmaceuticals to Present at RBC Capital Markets' Global Healthcare Conference
Feb 22, 7:00AM Marketwire
Feb 22, 7:00AM Marketwire
SciClone Pharmaceuticals Announces Final Settlement of Stockholder Derivative Litigation
Dec 15, 7:00AM Marketwire
Dec 15, 7:00AM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SCLN | 6.30 | -0.01 | -0.16% | 365.03M |
| SCL | 90.38 | -0.27 | -0.30% | 989.90M |
| SCKT | 2.110 | +0.01 | +0.47% | 10.16M |
| SCJ | 42.21 | +0.71 | +1.71% | |
| SCIL | 1.30 | +0.01 | +0.70% | 24.40M |
| SCI | 11.45 | +0.00 | +0.00% | 2.536B |
| SCHW | 12.46 | -0.06 | -0.48% | 15.92B |
| RPM | 26.36 | -0.02 | -0.08% | 3.463B |
| RPI | 1.37 | +0.00 | +0.00% | 14.22M |
| RP | 17.85 | -0.20 | -1.11% | 1.313B |
